Recent reports indicate the US economy experienced negative growth in the first quarter, creating a stark contrast with the stock market’s performance. This economic contraction comes at a time when ...

Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks. Compass Pathways is developing psilocybin as a treatment for depression. Viking ...

A selloff in tech stocks extended into a second day Wednesday, with investors rushing to sell some of the same shares that have powered indexes higher this year. The Nasdaq Composite ended the day ...

Palantir's AI platform is seeing widespread adoption in commercial and government applications. Q2 was Palantir's strongest quarter yet. Investors have to pay a premium to own Palantir's stock at ...

Procter & Gamble's growth has slowed, with weak cash flow and operational metrics not matching its earnings and sales performance. Despite its defensive profile and dividend history, current valuation ...

Investors seeking stocks that can put up dramatic gains in a short amount of time can find what they're looking for in the biotechnology industry. Investment bank analysts on Wall Street have tagged a ...